Newsmeme!
Discover News you didn't know existed
Double-blind Study
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Study tests if protein regrows spinal disks to avoid back surgeries
Published December 2, 2008, 9:12 am, KY3 Springfield
Many people suffer the debilitating effects of lower back pain. Relief could prove to be a shot away.
Patient Enrolment Completed in Phase II Clinical Trial for Allon's AL-108
Published December 2, 2008, 8:59 am, T-Net British Columbia
Vancouver, BC, December 2, 2008--(T-Net)--Allon Therapeutics Inc. (TSX:NPC) announced today that patient enrolment is complete in a Phase II clinical trial evaluating the safety and efficacy of the Company's proprietary drug candidate AL-108 in patients with schizophrenia-related cognitive impairment.
Landmark EchoCRT Trial Enrolls First European Patients
Published December 2, 2008, 8:32 am, Centre Daily Times
BIOTRONIK announced that the first European patients have been enrolled into the EchoCRT (Echocardiography guided Cardiac Resynchronization Therapy) trial by the team of physicians at Hospital Clínic in Barcelona, Spain, led by Professor Dr. Josep Brugada, Director of the Thorax Institute, Chairman of the Cardiology Department, EchoCRT Executive Committee Member and President of the European ...
Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
Published December 2, 2008, 8:27 am, EurekAlert!
( WeissComm Partners ) Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints. HZT 501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, demonstrated a statistically significant reduction in the ...
Landmark EchoCRT Trial Enrolls First European Patients
Published December 2, 2008, 8:06 am, Business Wire via Yahoo! Finance
BERLIN----BIOTRONIK announced that the first European patients have been enrolled into the EchoCRT trial by the team of physicians at Hospital Clínic in Barcelona, Spain, led by Professor Dr.
Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting ...
Published December 2, 2008, 6:27 am, PR Newswire via Yahoo! Finance
176b in Atrial Fibrillation Included in Scientific Program
Protalix BioTherapeutics Announces Completion of Enrollment for its Pivotal Phase III Clinical Trial of Gaucher Disease
Published December 2, 2008, 6:17 am, Centre Daily Times
Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that it has completed enrollment in the Company’s pivotal phase III clinical trial of prGCD, a proprietary plant cell expressed recombinant form of human glucocerebrosidase (GCD) for the treatment of Gaucher disease. Gaucher disease is a rare and serious lysosomal storage disorder in humans.
Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Published December 2, 2008, 5:30 am, PR Newswire via Yahoo! Finance
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT-501, met all primary endpoints.
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients ...
Published December 2, 2008, 5:30 am, PR Newswire via Yahoo! Finance
TorreyPines Therapeutics, Inc. today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome.
Protalix BioTherapeutics Announces Completion of Enrollment for its Pivotal Phase III Clinical Trial of Gaucher Disease
Published December 2, 2008, 5:30 am, Business Wire via Yahoo! Finance
CARMIEL, Israel----Protalix BioTherapeutics, Inc. , announced today that it has completed enrollment in the Company’s pivotal phase III clinical trial of prGCD, a proprietary plant cell expressed recombinant form of human glucocerebrosidase for the treatment of Gaucher disease.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |